Cecelia Perkins
Overview
Explore the profile of Cecelia Perkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Trizuljak J, Sperr W, Nekvindova L, Elberink H, Gleixner K, Gorska A, et al.
Allergy
. 2020 Feb;
75(8):1927-1938.
PMID: 32108361
Background: In indolent systemic mastocytosis (ISM), several risk factors of disease progression have been identified. Previous studies, performed with limited patient numbers, have also shown that the clinical course in...
12.
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, OConnell C, et al.
Blood
. 2020 Feb;
135(19):1696-1703.
PMID: 32107559
There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera (PV), as much of the published literature on the topic...
13.
Kluin-Nelemans H, Reiter A, Illerhaus A, van Anrooij B, Hartmann K, Span L, et al.
Leukemia
. 2019 Nov;
34(4):1090-1101.
PMID: 31740811
Systemic mastocytosis (SM) is frequently associated with eosinophilia. To examine its prevalence and clinical impact in all WHO classification-based subcategories, we analyzed eosinophil counts in 2350 mastocytosis patients using the...
14.
Sperr W, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink J, Gorska A, et al.
Lancet Haematol
. 2019 Nov;
6(12):e638-e649.
PMID: 31676322
Background: The WHO classification separates mastocytosis into distinct variants, but prognostication remains a clinical challenge. The aim of this study was to improve prognostication for patients with mastocytosis. Methods: We...
15.
Jawhar M, Schwaab J, Alvarez-Twose I, Shoumariyeh K, Naumann N, Lubke J, et al.
J Clin Oncol
. 2019 Sep;
37(31):2846-2856.
PMID: 31509472
Purpose: To develop a risk score for patients with advanced systemic mastocytosis (AdvSM) that integrates clinical and mutation characteristics. Patients And Methods: The study included 383 patients with AdvSM from...
16.
A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis
Gotlib J, Baird J, George T, Langford C, Reyes I, Abuel J, et al.
Blood Adv
. 2019 Jul;
3(15):2264-2271.
PMID: 31350306
There is an unmet need for effective therapies for advanced systemic mastocytosis (advSM). CD30 is expressed on the surface of neoplastic mast cells (MC) in more than 50% of patients...
17.
Valent P, Oude Elberink J, Gorska A, Lange M, Zanotti R, van Anrooij B, et al.
J Allergy Clin Immunol Pract
. 2018 Nov;
7(1):81-87.
PMID: 30416055
Mastocytosis is a unique hematologic neoplasm with complex biology and pathology and a variable clinical course. The disease can essentially be divided into cutaneous mastocytosis (CM) and systemic mastocytosis (SM)....
18.
Menghrajani K, Boonstra P, Mercer J, Perkins C, Gowin K, Weber A, et al.
Leuk Lymphoma
. 2018 Sep;
60(4):1036-1042.
PMID: 30234400
JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008...
19.
Ma V, Boonstra P, Menghrajani K, Perkins C, Gowin K, Mesa R, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Mar;
18(5):e201-e210.
PMID: 29574002
Introduction: In the era before Janus kinase (JAK) inhibitors, cytogenetic information was used to predict survival in myelofibrosis patients. However, the prognostic value of cytogenetics in the setting of JAK...